Neuro-ophthalmological paraneoplastic syndromes: a review

References

• Jacobson DM. Paraneoplastic diseases of neuro-ophthalmologic interest. In: Miller NR, Newman NJ, editors. Neuroophthalmology. Walsh and Hoyt's 1998.
   Google Scholar
• Thirkill CE. Retinal pigment epithelial hypersensitivity, an association with vision loss: RPE hypersensitivity complicating paraneoplastic retinopathies. Ocular Immunol Wain.2000;8:25–37.
   PubMedGoogle Scholar
• Berson EL, Lessell S. Paraneoplastic night blindness with malignant melanoma. Am J Ophthalmol. 1988; 106:307–311.
   PubMed Web of Science ®Google Scholar
• Gass JDM, Gieser RG, Wilkinson CP, Beahm DE, Pautler SE. Bilateral diffuse uveal melanocytic proliferation in patients with occult carcinoma. Arch Ophthalmol. 1990; 108:527–533.
   Google Scholar
• Thirkill CE, FitzGerald P, Sergott RC, Roth A, Tyler NK, Keltner JL. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic nerve and cancer cells. N Engl J Med. 1989;321: 1589–1594.
   PubMed Web of Science ®Google Scholar
• Thirkill CE. Lung cancer-induced blindness. Lung Cancer. 1996;14: 253–264.
   PubMedGoogle Scholar
• Boeck K, Hofmann S, Klopfer M, Ian U, Schmidt T, Engst R, Thirkill CE, Ring J. Melanoma-associated paraneoplastic retinopathy: case report and review of the literature. Br J Dermatol. 1997;137:457–460.
   PubMed Web of Science ®Google Scholar
• Tang RA, Kellaway J, Young SE. Ophthalmic complications of systemic cancer. Oncology. 1991;5:59–71.
   Google Scholar
• Malik S, FurIan AJ, Sweeny PJ, Kasmorsk GS, Wong M. Optic neuropathy: a rare paraneoplastic syndrome. J Clin Ophthalmol. 1992; 12:137–141.
   Google Scholar
• Hoogenraad TU, Sanders EACM, Tan KEWP. Paraneoplastic optic neuropathy with histopathology verification of absence of meningeal metastases. Neuro-Ophthalmology. 1989;9:247–250.
   Google Scholar
• Oohira A, Inoue T, Fukuda N, Uchida KI. A case with paraneoplastic optic neuropathy presenting bitemporal hemianopsia. Neuro-Ophthalmology. 1991;1 I: 325–328. malignancy. In: Tasman W, Jaeger EA, editors. Duane's clinical ophthalmology. Philadelphia: JB Lipincott, 1989; Vol. 5, Ch. 34,1–7.
   Google Scholar
• Yu Z, Kryzer TJ, Griesmann GE, Kim KK, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer
   Google Scholar
• Luiz JE, Lee AG, Keltner JL, Thirkill CE, Lai EC. Paraneoplastic optic neuropathy and autoantibody production in small-cell carcinoma of the lung. J Neuro-ophthalmoL
   Google Scholar
• Honnorat J, Antoine JC, Derrington E, Aguera M, Belin ME Antibodies to a subpopulation of glial cells and a 66 kD developmental protein in patients with paraneoplastic neurological syndrome. J Neurol
   Google Scholar
• Antoine JC, Honnorat J, Vocanson C, Koenig F, Aguera M, Belin MF, Michel D. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with a developmental protein of brain and retina. J Neurol ScL 1993;I 17:215–
   Google Scholar
• De la Sayette V, Bertran F, Honnorat J, Schaeffer S, Inglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with
   Google Scholar
• Lieberman FS, Odel J, Hirsh J, Heinemann M, Michaeli J, Posner J. Bilateral optic neuropathy with 414–416.
   Google Scholar
• Charif M, Blard JM, Pages M. Syndrome POEMS � r�v�lation ophtalmique. Rev Neurol (Paris). 2000;156:1151�1153
   Google Scholar
• Bolling JP, Brazis PW. Optic disc swelling with peripheral neuropathy, organomegaly, endocrinopathy, monoclonal gammapathy and skin changes (P.O.E.M.S. syndrome). Am
   Google Scholar
• Shakin EP, Shields JA. The eye and ocular adnexa in systemic E, Cavaletti G. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J NeuroL 1997;244:85–89.
   Google Scholar
• DeAngelis LM, Yahalom J, Heinemann MH, Cirrincione C, Thaler HT, Krol G. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology. 1990;40: 8o–86.
   Google Scholar
• Greenberg HS, Ensminger WD, Chandler WF, Layton PB, Junck L, Knake J, Vine AK. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg. 1984; 61:423–429.
   Google Scholar
• Poisson M, Chiras J, Fauchon F, Debussche C, Delattre JY. Treatment of malignant glioma by intra-arterial, infra-ophthalmic infusion of HeCNU I-(2-chloroethyl)-i-nitroso-3-(2-hydroxyethyl)-urea. A phase II study. J NeurooncoL 1990;8: 255–262.
   Google Scholar
• Newton HB, Page MA, Junck L, Greenberg HS. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neurosurg. 1989;7:39–45.
   Google Scholar
• Stewart DJ, Belanger JME, Grahovac Z, Curuvija S, Gionet LR, Aitken SE, Hugenholtz H, Benoit BG, Dasilva YE Phase I study of intracarotid administration of carboplatin. Neurosurgery. 1992;30: 512–517.
   PubMed Web of Science ®Google Scholar
• Salomon GE, Chutorian AM. Opsoclonus and occult neuroblastoma. N Engl J Med. 1968;279:475–477.
   PubMedGoogle Scholar
• Luque FA, Furneaux HM, Ferzinger R, Rosenblum MK, Wray SH, Schold SC, Glantz MJ, Jaeckle KA, Biran H, Lesser M, Paulsen WA, River ME, Posner JB. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29: 241–251.
   Google Scholar
• Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, Liszka-Setinek U, Marzorati L, Wondrusch
   Google Scholar
• Casado JL, Gil-Peralta A, Graus F, Arenas C, Lopez JM, Alberca R. Anti-Ri antibodies associated with opsoclonus and progressive encephalomyelitis with rigidity. Neurology. 1994;44:1521–1522.
   PubMedGoogle Scholar
• Cher LM, Hochberg FH, Teruya J, Nitschke M, Velenzuela RE, Schmanhmann JD, Herbert M, Rosas HD, Stowell C. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoabsorption. Arch NeuroL 1981;38:780–781.
   Google Scholar
• Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest. 1992;66:331–336.
   PubMed Web of Science ®Google Scholar
• Voltz RD, Albrich WC, Nagele A, Schumm F, Wick M, Freiburg A, Gautel M, Thaler HT, Aarli J, Kirchner TH, Hohlfeld R. Paraneoplastic myasthenia gravis: detection of anti-MGT 30 (titin) antibodies predicts thymic epithelial tumor. Neurology. 1997;49: 1454–1457:
   Google Scholar
• Quilichini R, Fuentes P, Metge G, Lafeuillade A, Albatro J. Syndrome myasthénique révélateur d'une maladie de Hodgkin. Rev Neurol (Paris). 1994;150:81–82.
   PubMed Web of Science ®Google Scholar
• Abrey LE. Association of myasthenia gravis with extrathymic Hodgkin's lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy. Neurology. 1995;45:1019.
   PubMed Web of Science ®Google Scholar
• Bowen JD, Kidd PP. Myasthenia gravis associated with T helper cell lymphoma. Neurology. 1987;37: 1405–1408.
   PubMed Web of Science ®Google Scholar
• Campello Morer I, Marta Moreno E, Capablo Liesa JL, Alvarez Alegret R, Giraldo Castellanos P. Miastenia grave y linfoma no hodginiano. Neurologia. 1995;io: 246–248.
   Google Scholar
• Moorthy G, Behrens MM, Drachman DB, Kirham TH, Knox DL, Miller NR, Slamovitz TL, Zinreich SI Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians. Neurology. 1989;39: 119)–1154:
   Google Scholar
• Straube A, Witt TN. Oculo-bulbar myasthenic symptoms as the sole sign of tumour involving or compressing the brain stem. J NeuroL 1990;237:369–371.
   PubMedGoogle Scholar
• Hejna M, Haberl I, Raderer M. Non surgical management of malignant thymoma. Cancer. 1999;85:1871–1884.
   Google Scholar
• Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, Dalmau J. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med. 1999;34o:1788–1795.
   Google Scholar
• Dalmau J, Gultekin SH, Voltz R, Hoard R, Deschamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR. Mal, a novel neuro-and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain. 1999;122:27–39.
   PubMed Web of Science ®Google Scholar
• Berger PS, Bataini JP. Radiation-induced cranial nerve palsy. Cancer. 1977;40:152–155.
   PubMed Web of Science ®Google Scholar
• Lessell S, Lessell IM, Rizzo IF Ocular neuromyotonia after radiation therapy. Am J OphthalmoL 1986;102:766–770.
   PubMed Web of Science ®Google Scholar
• Sandler SG, Tobin W, Henderson ES. Vincristine-inducd neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969;19:367–374:
   Google Scholar
• Masunuru K, Darnell RB. Paraneoplastic neurologic disease antigens: ma binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci. 2001;24:239–262.
   PubMedGoogle Scholar
• Posner JB. Neurologic complications of cancer. Philadelphia: Davis, 1995; 353–384.
   Google Scholar
• Dropcho EJ, Dalmau J, Greenlee JE, Laov N, Leung DK, Sanders DB. Paraneoplastic disorders. Continuum series. 1999;5(6) December.
   Google Scholar